Collaborative study to establish the first international standard for quantification of anti-HPA-1a

D. Allen, R. Rigsby, H. Bessos, J. Berry, D. W. Wilson, W. Ouwehand, Stanislaw Urbaniak, P. Metcalfe

    Research output: Contribution to journalArticle

    20 Citations (Scopus)

    Abstract

    Background and Objectives This report describes the production of a freeze-dried preparation of pooled human plasma, containing immunoglobulin G (IgG) antibodies against the human platelet antigen 1a (HPA-1a). The material, coded 03/152, is proposed as an International Standard containing 100 arbitrary units of anti-HPA-1a for use in quantitative assays to determine the anti-HPA-1a activity in clinical samples.

    Materials and Methods Plasma samples containing potent anti-HPA-1a were pooled and freeze dried in 1-ml ampoules. In addition, three individual plasma samples were selected which had varying levels of anti-HPA-1a activity. The anti-HPA-1a activity of these three samples was determined by using a variety of quantitative assays with the proposed standard as a reference.

    Results An international collaborative study, which was part of the 2004 ISBT Platelet Immunology Workshop, involved 39 laboratories in 24 countries and showed that the anti-HPA-1a activity in three test samples could be reliably determined by using the proposed standard.

    Conclusions Laboratories can use this standard to measure the anti-HPA-1a activity in patient's samples. Further studies are required to determine the relationship between anti-HPA-1a activity and clinical outcome in patients with neonatal alloimmune thrombocytopenia (NAIT).

    Original languageEnglish
    Pages (from-to)100-104
    Number of pages4
    JournalVox Sanguinis
    Volume89
    DOIs
    Publication statusPublished - 2005

    Keywords

    • anti-HPA-1a
    • NAIT
    • platelet alloantibody detection
    • quantitation
    • NEONATAL ALLOIMMUNE THROMBOCYTOPENIA
    • ANTI-D
    • BIOLOGICAL STANDARDS
    • IMMUNOGLOBULIN
    • ANTIBODIES
    • MANAGEMENT
    • EVALUATE
    • NEWBORN
    • 1A

    Cite this

    Allen, D., Rigsby, R., Bessos, H., Berry, J., Wilson, D. W., Ouwehand, W., ... Metcalfe, P. (2005). Collaborative study to establish the first international standard for quantification of anti-HPA-1a. Vox Sanguinis, 89, 100-104. https://doi.org/10.1111/j.1423-0410.2005.00669.x

    Collaborative study to establish the first international standard for quantification of anti-HPA-1a. / Allen, D.; Rigsby, R.; Bessos, H.; Berry, J.; Wilson, D. W.; Ouwehand, W.; Urbaniak, Stanislaw; Metcalfe, P.

    In: Vox Sanguinis, Vol. 89, 2005, p. 100-104.

    Research output: Contribution to journalArticle

    Allen, D, Rigsby, R, Bessos, H, Berry, J, Wilson, DW, Ouwehand, W, Urbaniak, S & Metcalfe, P 2005, 'Collaborative study to establish the first international standard for quantification of anti-HPA-1a', Vox Sanguinis, vol. 89, pp. 100-104. https://doi.org/10.1111/j.1423-0410.2005.00669.x
    Allen, D. ; Rigsby, R. ; Bessos, H. ; Berry, J. ; Wilson, D. W. ; Ouwehand, W. ; Urbaniak, Stanislaw ; Metcalfe, P. / Collaborative study to establish the first international standard for quantification of anti-HPA-1a. In: Vox Sanguinis. 2005 ; Vol. 89. pp. 100-104.
    @article{dd463cc7ab6a482481c7e9374b6adf34,
    title = "Collaborative study to establish the first international standard for quantification of anti-HPA-1a",
    abstract = "Background and Objectives This report describes the production of a freeze-dried preparation of pooled human plasma, containing immunoglobulin G (IgG) antibodies against the human platelet antigen 1a (HPA-1a). The material, coded 03/152, is proposed as an International Standard containing 100 arbitrary units of anti-HPA-1a for use in quantitative assays to determine the anti-HPA-1a activity in clinical samples.Materials and Methods Plasma samples containing potent anti-HPA-1a were pooled and freeze dried in 1-ml ampoules. In addition, three individual plasma samples were selected which had varying levels of anti-HPA-1a activity. The anti-HPA-1a activity of these three samples was determined by using a variety of quantitative assays with the proposed standard as a reference.Results An international collaborative study, which was part of the 2004 ISBT Platelet Immunology Workshop, involved 39 laboratories in 24 countries and showed that the anti-HPA-1a activity in three test samples could be reliably determined by using the proposed standard.Conclusions Laboratories can use this standard to measure the anti-HPA-1a activity in patient's samples. Further studies are required to determine the relationship between anti-HPA-1a activity and clinical outcome in patients with neonatal alloimmune thrombocytopenia (NAIT).",
    keywords = "anti-HPA-1a, NAIT, platelet alloantibody detection, quantitation, NEONATAL ALLOIMMUNE THROMBOCYTOPENIA, ANTI-D, BIOLOGICAL STANDARDS, IMMUNOGLOBULIN, ANTIBODIES, MANAGEMENT, EVALUATE, NEWBORN, 1A",
    author = "D. Allen and R. Rigsby and H. Bessos and J. Berry and Wilson, {D. W.} and W. Ouwehand and Stanislaw Urbaniak and P. Metcalfe",
    year = "2005",
    doi = "10.1111/j.1423-0410.2005.00669.x",
    language = "English",
    volume = "89",
    pages = "100--104",
    journal = "Vox Sanguinis",
    issn = "0042-9007",
    publisher = "Wiley-Blackwell",

    }

    TY - JOUR

    T1 - Collaborative study to establish the first international standard for quantification of anti-HPA-1a

    AU - Allen, D.

    AU - Rigsby, R.

    AU - Bessos, H.

    AU - Berry, J.

    AU - Wilson, D. W.

    AU - Ouwehand, W.

    AU - Urbaniak, Stanislaw

    AU - Metcalfe, P.

    PY - 2005

    Y1 - 2005

    N2 - Background and Objectives This report describes the production of a freeze-dried preparation of pooled human plasma, containing immunoglobulin G (IgG) antibodies against the human platelet antigen 1a (HPA-1a). The material, coded 03/152, is proposed as an International Standard containing 100 arbitrary units of anti-HPA-1a for use in quantitative assays to determine the anti-HPA-1a activity in clinical samples.Materials and Methods Plasma samples containing potent anti-HPA-1a were pooled and freeze dried in 1-ml ampoules. In addition, three individual plasma samples were selected which had varying levels of anti-HPA-1a activity. The anti-HPA-1a activity of these three samples was determined by using a variety of quantitative assays with the proposed standard as a reference.Results An international collaborative study, which was part of the 2004 ISBT Platelet Immunology Workshop, involved 39 laboratories in 24 countries and showed that the anti-HPA-1a activity in three test samples could be reliably determined by using the proposed standard.Conclusions Laboratories can use this standard to measure the anti-HPA-1a activity in patient's samples. Further studies are required to determine the relationship between anti-HPA-1a activity and clinical outcome in patients with neonatal alloimmune thrombocytopenia (NAIT).

    AB - Background and Objectives This report describes the production of a freeze-dried preparation of pooled human plasma, containing immunoglobulin G (IgG) antibodies against the human platelet antigen 1a (HPA-1a). The material, coded 03/152, is proposed as an International Standard containing 100 arbitrary units of anti-HPA-1a for use in quantitative assays to determine the anti-HPA-1a activity in clinical samples.Materials and Methods Plasma samples containing potent anti-HPA-1a were pooled and freeze dried in 1-ml ampoules. In addition, three individual plasma samples were selected which had varying levels of anti-HPA-1a activity. The anti-HPA-1a activity of these three samples was determined by using a variety of quantitative assays with the proposed standard as a reference.Results An international collaborative study, which was part of the 2004 ISBT Platelet Immunology Workshop, involved 39 laboratories in 24 countries and showed that the anti-HPA-1a activity in three test samples could be reliably determined by using the proposed standard.Conclusions Laboratories can use this standard to measure the anti-HPA-1a activity in patient's samples. Further studies are required to determine the relationship between anti-HPA-1a activity and clinical outcome in patients with neonatal alloimmune thrombocytopenia (NAIT).

    KW - anti-HPA-1a

    KW - NAIT

    KW - platelet alloantibody detection

    KW - quantitation

    KW - NEONATAL ALLOIMMUNE THROMBOCYTOPENIA

    KW - ANTI-D

    KW - BIOLOGICAL STANDARDS

    KW - IMMUNOGLOBULIN

    KW - ANTIBODIES

    KW - MANAGEMENT

    KW - EVALUATE

    KW - NEWBORN

    KW - 1A

    U2 - 10.1111/j.1423-0410.2005.00669.x

    DO - 10.1111/j.1423-0410.2005.00669.x

    M3 - Article

    VL - 89

    SP - 100

    EP - 104

    JO - Vox Sanguinis

    JF - Vox Sanguinis

    SN - 0042-9007

    ER -